Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
An Open-Label, Randomized Naturalistic Study to Evaluate the Incidence of Hypoglycemia Comparing Sitagliptin With Sulfonylurea Treatment in Patients With Type 2 Diabetes During Ramadan Fasting	MSD	Completed	Sitagliptin	4	MK0431-263	Al-Noor Specialist Hospital (Makkah), Armed Forces Hospital (Al-Hada), King Fahad University Hospital (Al-Khobar), Riyadh Care Hospital, Al Alam Medical Center (Riyadh)
A 20-week Study Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients Uncontrolled on NPH Insulin	Novonordisk	Completed	BIAsp 30 / Metformin	4	BIAsp 3968	King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz University Hospital (Jeddah), Armed Forces Hospital (Al-Hada)
A multicentre, prospective observational cohort study to assess the effects of vildagliptin relative to sulphonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan	Novartis	Completed	Vildagliptin / Sulphonylurea / Metformin	4	CLAF237A-MAX-AE-02	Soliman Fakeeh Hospital (Jeddah)
A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating On-Treatment Predictors of Response in Subjects With HBeAg Positive and HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS(R) (Peginterferon Alfa-2a 40KD)	Roche	Completed	Pegasys	4	MV22009	King Fahad University Hospital (Al-Khobar), Armed Forces Hospital (Kharj)
UNraveling nAMD real life Clinical management and Outcome with intraVitrEal Ranibizumab injection – A retrospective analysis (UNCOVER)	Novartis	Completed	Ranibizumab	4	CRFB0021	King Khaled Eye Specialist Hospital (Riyadh)
A double blind, Double Dummy, Randomized, Multi-Centre study to assess the tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy with Metformin in Muslim Patients with Type 2 Diabetes Fasting During Ramadan.	Novartis	Completed	Vildagliptin /Gliclazide / Metformin	4	CLAF237A2411	King Fahad University Hospital (Al-Khobar)_ King Abdulaziz Medical City NG (Riyadh)
A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk	Boehringer Ingelheim	Completed	BI 10773	3	1245.25	King Fahad Medical City (Riyadh)
Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma	Roche	Completed	Bevacizumab	3	MO22923	King Fahad Medical City (Riyadh)_ King Fahad Specialist Hospital (Dammam)
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency	Synageva	Completed	Sebelipase alfa (SBC-102)	2	LAL-CL03	King Faisal Specialist Hospital and Research Center (Riyadh)
Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS	Eagle Pharmaceuticals	Completed	Dantrolene	2	EGL-4104-C-1502	King Fahad Medical City (Riyadh)